Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) Debt to Equity (2021)

Historic Debt to Equity for ARS Pharmaceuticals (SPRY) over the last 1 years, with Q4 2021 value amounting to -$0.16.

  • ARS Pharmaceuticals' Debt to Equity changed N/A to -$0.16 in Q4 2021 from the same period last year, while for Dec 2021 it was -$0.16, marking a year-over-year change of. This contributed to the annual value of -$0.16 for FY2021, which is N/A changed from last year.
  • Per ARS Pharmaceuticals' latest filing, its Debt to Equity stood at -$0.16 for Q4 2021.
  • ARS Pharmaceuticals' Debt to Equity's 5-year high stood at $0.0 during Q1 2021, with a 5-year trough of -$0.16 in Q4 2021.